 Connection
Jeffrey Olson to Antibodies, Monoclonal
This is a "connection" page, showing publications Jeffrey Olson has written about Antibodies, Monoclonal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.783 |
|
|
|
-
Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun; 27(3):219-24.
Score: 0.243
-
Olson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol. 2007 Sep; 125(9):1221-4.
Score: 0.188
-
Rudometkin N, Mandava N, Deane K, Olson JL. Infliximab in uveitis treatment. Arch Ophthalmol. 2006 Aug; 124(8):1211; author reply 1211-2.
Score: 0.175
-
Strong A, Huvard M, Olson JL, Mark T, Capitena Young C. Daratumumab-induced Choroidal Effusion: A Case Report and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2020 12; 20(12):e994-e997.
Score: 0.116
-
Bennett JL, Thomas S, Olson JL, Mandava N. Treatment of nonarteritic anterior ischemic optic neuropathy with intravitreal bevacizumab. J Neuroophthalmol. 2007 Sep; 27(3):238-40.
Score: 0.047
-
Dixon JA, Oliver SC, Olson JL, Mandava N. VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs. 2009 Oct; 18(10):1573-80.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|